SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today presented a trial-in-progress poster on SBT6050-201 at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting, held virtually from November 10-14, 2021. SBT6050-201 is a Phase 1/2 study evaluating SBT6050 in combination with trastuzumab deruxtecan (Enhertu), or with trastuzumab (Herceptin) and tucatinib (Tukysa) with or without capecitabine, in patients with HER2-expressing or HER2-amplified gastroesophageal, non-small cell lung, breast, and colorectal cancers.
“SBT6050 was designed to enable combinations with trastuzumab-containing regimens, which are foundational in the standard of care for HER2-positive solid tumors,” said Naomi Hunder, M.D., chief medical officer of Silverback Therapeutics. “There is compelling scientific and clinical rationale to combine SBT6050 with these regimens. Importantly, in addition to the trastuzumab component of these regimens, they each contain a cytotoxic component that drives immunogenic cell death, releasing tumor neoantigens. SBT6050 activates dendritic cells, potentially enhancing neoantigen presentation to T cells and amplifying the anti-tumor response. SBT6050 may also enhance trastuzumab-mediated antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis. We look forward to initiating clinical evaluation of these combinations in the first quarter of 2022.”
The poster is now available on the SITC website and on the Silverback website here. Details are as follows:
Poster Title: A phase 1/2 study of SBT6050 combined with trastuzumab deruxtecan (T-DXd) or trastuzumab and tucatinib with or without capecitabine in patients with HER2-expressing or HER2-amplified cancers
Presenter: Sam J. Klempner, MD
Category: Clinical Trials in Progress
Abstract Number: 393
About SBT6050
SBT6050 is the first of a new class of targeted immuno-oncology agents designed to direct a TLR8 agonist linker-payload to activate myeloid cells in tumors expressing moderate to high levels of HER2. TLR8 is expressed in myeloid cell types prevalent in human tumors and TLR8 agonism can activate a broad spectrum of anti-tumor immune mechanisms, including pathways involved in the innate and adaptive immune response. SBT6050 was specifically designed to bind to the HER2 sub-domain II, the pertuzumab epitope, to enable combinations with trastuzumab-containing therapies. SBT6050 is currently being evaluated in a Phase 1/1b trial in patients with advanced or metastatic HER2-expressing or amplified solid tumors.
About Silverback Therapeutics
Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Silverback’s platform enables the strategic pairing of proprietary payloads that modulate key disease modifying pathways with monoclonal antibodies directed at specific disease sites. Initially, Silverback is creating a new class of targeted immuno-oncology agents that direct a TLR8 agonist myeloid cell activator to the tumor microenvironment in solid tumors to promote cancer cell killing. Silverback Therapeutics is located in Seattle, Washington. To learn more, visit www.silverbacktx.com.
Forward-Looking Statements
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, Silverback’s plans and ability to bring new treatments to patients in need, including potential combination efforts, and the progress and expected timing of Silverback’s drug development programs and clinical trials. Factors that may cause actual results to differ materially include the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Silverback may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings and applications, risks associated with reliance on third parties to successfully conduct clinical trials, the risks associated with reliance on outside financing to meet capital requirements, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "promise," "potential," "expects," "plans," "anticipates," "intends," "continues," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties that Silverback faces, please refer to Silverback’s periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Silverback assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
